Lyell is an immuno-oncology company dedicated to reprogramming T cells to achieve curative therapies for solid tumors. The company takes a deliberate approach to solving what it believes to be the major barriers to successful adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is combining its proprietary ex vivo genetic and epigenetic reprogramming technologies that address these barriers with T cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptors (CARs). 

Biotechnology

Therapeutics

Lyell Immunopharma

Lynn Seely

Artem Yankov

Pradeep Ravindra

Chris Michon

Manjit Dokal

Stasiu Nowak

Julie Urvater

Jennifer Fleischer

Cynthia Shumate

Vonnie Vo

Erik Green

Senai Teklemichael

Marly Puckett

Eric Hoffmann

Karen Duffy-Simons

Julie Jeffery

Dana Langworthy

Alisha Lewis

Rick Watt

Danielle Kulman

Kimberly Henson

Wen Liu

Joanna Karas

Shipra G.

Joseph Maguire

Ellen Rose

Matthew Lang

Charles Newton

Tina Albertson

Gary Lee

Stephen Hill

The board of directors at Lyell Immunopharma has a history of working in the medical field and being highly educated. Many of the members have worked as principal investigators and postdoctoral fellows at renowned institutions such as the National Institutes of Health and Memorial Sloan Kettering Cancer Center. In terms of education, the board members have degrees in medicine from schools like The Johns Hopkins University.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at Lyell Immunopharma

Leadership Team

CEO and Executive Team